Aphria Inc. has announced a deal to produce and sell medical marijuana transdermal patches. These cannabis patches were developed by scientists at Massachusetts Institute of Technology.
According to the Canadian cannabis company, it has signed a licensing agreement with Manna Molecular Science LLC to produce and sell these cannabis patches.
Manna Molecular Science, which was founded in 2015 by a group of cannabis industry experts and pharmaceutical chemists, creates safe cannabis-infused products that can be used as a popular household therapy. Its state-of-the-art transdermal patches contain cannabis oil and are currently available in New Hampshire, Massachusetts, and Nevada.
The Aphria-Manna deal
Pursuant to the terms of their deal, the American company will give Aphria “exclusive preferred vendor status” for a five-year period. They will also give Aphria an exclusive license to produce, market, and distribute Manna patches.
In a news release, Manna said that the deal with Aphria gives them “the reach to distribute their patches at a global level.”
Meanwhile, Aphria said that leveraging Manna’s formulations, equipment, and processes, they will produce and sell cannabis patches under their established suite of medical and adult-use brands. Through this, they get to evolve cannabis medicine for everyday life.
Aphria President Jakob Ripshtein said that they are “excited to offer innovative new ways for consumers to interact with cannabis.”
What’s special about these patches?
The cannabis patch was developed by pharmaceutical scientists from MIT using cutting-edge research methods and product design. It works for all cannabinoids and high-quality, whole-plant cannabis extracts are printed on each patch.
The pharmaceutical-grade patches are latex and allergen-free. They deliver cannabis doses through the user’s skin over a period of 12 hours.
Their release, however, did not specify what ailments are targetted by the patches.
Other innovative cannabis products coming up
Elsewhere in Canada’s medical cannabis industry, Tilray could end up making CBD-infused products like muscle wraps and foot balms that would be distributed mainstream by U.S. retailers.